Table I.

Plating efficiency and micronucleus frequency at 0 Gy.

Variable	Without nicotinamide or MTH	With nicotinamide	With MTH
Plating efficiency (%)
Without bevacizumab
Without 10B-carrier	84.4±8.2	81.4±7.3	83.5±8.7
With BPAc	76.9±7.7	69.9±6.5	73.9±7.3
With BSHd	81.4±8.3	74.9±6.3	78.9±6.8
With bevacizumab
Without 10B-carrier	80.1±8.0	76.3±7.1	78.4±8.3
With BPA	69.6±7.1	64.8±6.2	68.8±7.0
With BSH	74.1±7.7	69.8±7.2	73.8±7.1
Micronucleus frequency
Without bevacizumab
Total cell population
Without 10B-carrier	0.050±0.008	0.057±0.006	0.054±0.005
With BPA	0.063±0.008	0.081±0.008	0.077±0.007
With BSH	0.059±0.008	0.078±0.009	0.074±0.008
Quiescent cell population
Without 10B-carrier	0.077±0.008	0.084±0.009	0.081±0.009
With BPA	0.091±0.009	0.110±0.011	0.105±0.010
With BSH	0.095±0.009	0.120±0.011	0.115±0.011
With bevacizumab
Total cell population
Without 10B-carrier	0.058±0.008	0.068±0.007	0.069±0.007
With BPA	0.071±0.008	0.092±0.009	0.092±0.009
With BSH	0.067±0.008	0.089±0.009	0.089±0.009
Quiescent cell population
Without 10B-carrier	0.083±0.008	0.086±0.009	0.087±0.009
With BPA	0.097±0.009	0.112±0.011	0.111±0.011
With BSH	0.101±0.009	0.122±0.011	0.121±0.011

Data are presented as mean ± standard error (n=9). MTH, mild temperature hyperthermia; BPA, l-para-boronophenylalanine-¹⁰B; BSH, sodium mercaptoundecahydrododecaborate-¹⁰B.